



HEALTH INFORMATION *designs*



West Virginia Department of Health and Human Resources

Bureau for Medical Services Drug Utilization Review Board

September 20, 2017

Second Quarter 2017

| | | |
|---------------------|-------|-------|
| ○ Profiles Reviewed | 1,206 | |
| ○ Cases Identified | 900 | |
| ○ Letters Mailed | | |
| ○ Prescribers | 1,105 | |
| ○ Pharmacies | 971 | |
| ○ Responses | | |
| ○ Prescribers | 179 | 16.2% |
| ○ Pharmacies | 174 | 17.9% |



Second Quarter 2017

April RDUR Criteria:

- **Controlled substances**
- **Drug-Drug Conflicts:**
 - **SSRI's & TCAs**
 - **Anticoagulants**
 - **Benzodiazepines & buspirone**
 - **ACEI's & NSAIDs**
 - **NSAIDs & Beta Blockers**
- **Drug-Disease Interactions**
 - **NSAID use in patients with diabetes**



Second Quarter 2017

April Educational Intervention:

○ Triple Drug Combination

- Patients on an opioid + skeletal muscle relaxant + benzodiazepine
- Education on risk of CNS depression, abuse/dependence, and diversion
- Sent to all prescribers of at least one of the above for patients on the combination
 - Cases Reviewed: 548
 - Letters Sent: 652



Second Quarter 2017

May RDUR Criteria:

- **Controlled substances**
- **Drug-Disease interactions**
 - **Aripiprazole**
 - Patients with seizure disorders
 - Patients with cardiovascular or cerebrovascular disease
 - **NSAIDS**
 - Patients with cardiovascular disease
 - Patients with renal impairment
- **Drug-Drug Interactions:**
 - **NSAIDS /Warfarin**
 - **Duplication of NSAIDS**
 - **Cyclobenzaprine and TCAs**
 - **SSRI's and other serotonergic agents**
 - **Stimulants and other serotonergic agents**



Second Quarter 2017

June RDUR Criteria:

- **Controlled substances**
- **Underutilization**
 - Long-term asthma controllers
- **Therapeutic duplication**
 - Antiulcer agents
 - Anxiolytics
 - Loop diuretics
 - Skeletal Muscle Relaxants
- **Clinical Appropriateness**
 - Polypsychotherapy



Second Quarter 2017

June Educational Intervention:

- **Identify new members on non-formulary test strips**
 - **Sent to prescriber's with patients on True Metrix Diabetic Products to inform affected patients**
 - Single letter to prescriber with all patients affected.
 - **Letters sent included all potentially affected patients.**
 - Cases Reviewed: 2,798
 - Letters Sent: 1,029



Second Quarter 2017

Proposed Educational Interventions

- **Opioid MME restriction for new members**
 - December mailed 1,297 MD letters for 4,735 affected members in current population
- **Therapy with both a long-acting benzodiazepine and sedative/hypnotic**
 - MD letters to patients with concurrent or alternating claims
- **FDA's Drug Safety Communications**
 - Codeine and tramadol use in children



Second Quarter 2017

Distribution of Cases:

- **Drug-Disease Interactions: 12%**
 - Patients receiving a drug that may worsen or precipitate a medical condition.
- **Drug-Drug Conflict: 61%**
 - Patients receiving two or more drugs that may interact and produce unpredictable and undesirable effects.
- **Over-utilization: 8%**
 - Patients taking medications in apparently excessive doses or for excessive lengths of time.
- **Non-compliance: 6%**
 - Patients not taking medication according to directions, resulting in possible sub-therapeutic response.
- **Clinical Appropriateness: 12%**
 - Patients who are taking medications for treatment of a disease for which the medication is not standard of care.



Second Quarter 2017

Evaluation

- **Extremely useful** **27**
- **Useful** **61**
- **Somewhat useful** **24**
- **Neutral** **10**
- **Not useful** **21**



Second Quarter 2017

Lock-In

| | |
|-------------------------|-------|
| • Profiles Reviewed | 152 |
| • Total Cases | 53 |
| • Case Rate | 34.9% |
| • Warning Cases | 47 |
| • Lock-In (LI) Cases | 4 |
| • Cases Continued in LI | 2 |
| • Cases Removed from LI | 0 |



Questions?

